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The paper by Zhang and colleagues published in this issue 
of Annals of Translational Medicine reports on the value of 
using high definition of HLA typing in the setting of lung 
transplantation (1).
The results obtained by analyzing a cohort of 59 lung 
transplant recipients indicate that patients with a high 
degree of HLA mismatch, as determined using both genetic 
sequencing and the matchmaker software, are at higher 
risk of perioperative primary graft dysfunction (PGD) and 
acute rejection (AR). In addition, the authors suggest that 
systematic monitoring of donor specific antibodies (DSA) 
in the post-transplant setting may be helpful in identifying 
patients at high risk for AR. These conclusions suggest that 
improved HLA typing methods, as well as immunologic 
monitoring of transplanted patients may be helpful in early 
identification of rejection episodes. 
HLA alleles were originally identified using sera from 
highly immunized individuals, typically patients that 
had received multiple blood transfusions or multiparous 
women, leading to the identification of groups of alleles 
defined by a panel of antibodies. Historically, HLA Class 
I was the first identified, with specificities defined through 
a series of consensus conferences known as International 
Histocompatibility Workshops in the late sixties and 
seventies (2). Typing by serology was then widely used 
worldwide also thanks to the implementation of consumer-
friendly assays. While this kind of approach is simple, quick 
and low-cost, it offers a low-resolution picture of the HLA 
region, without providing allele identification and—in some 
instances—not resolving typing. HLA gene identification 
started only in the eighties with the progressive cloning 
of Class I and Class II genes. Since the beginning of the 
nineties, molecular tools for genetic typing of the HLA 
region became available. These tools exploit the polymerase 
chain reaction (PCR) and are based on the design of 
primers (SSP) or of oligonucleotides (SSO) that are specific 
for a given group of alleles, or—in some instances—for a 
specific allele. PCR-amplified sequences can then be run 
on a gel, as is the case for SSP, posing limitations on its use. 
In fact, SSP was originally set up to type for DRB1 alleles, 
which were unsatisfactorily recognized by antibodies. 
Because gel resolution of the PCR products requires 
extensive manipulation and is hardly scalable, RT-PCR 
approaches were implemented, which are now mostly used 
in the setting of cadaveric donor typing, considering the 
rapidity and versatility of the assay, which is however quite 
costly and thus not yet universally employed. Alternative 
molecular methods use probes that can be immobilized on 
a membrane or a bead and mixed with the denatured DNA 
under analysis, which has been previously biotinylated. All 
these systems generally offer a low/intermediate resolution 
typing, even though for SSO typing newer kits allow to 
resolve most allelic combinations. The gold-standard 
for allelic typing for all loci is direct sequencing of the 
polymorphic exons of the HLA Class I (exons 2, 3 and 4) 
and Class II (exon 2) either by Sanger or by next generation 
sequencing. However, the two latter approaches are 
technically complex and require longer time compared to 
the other molecular methods. In addition, typing by NGS 
cannot be performed for a single patient, but is generally 
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performed for multiple samples in a row, restricting its 
employment by small/medium centers. Clinical applications 
of NGS typing has been developed in Hemopoietic Stem 
cell Transplantation. Typing costs vary widely, with SST 
being the least expensive and RT-PCR/NGS being the 
most expensive techniques.
Today, a donor and a recipient should be typed for HLA 
A, B and C genes (Class I) and DRB1, DRB3, DRB4, DRB5, 
DQA1, DQB1, DPA1 and DPB1 genes. Class II typing 
is complicated by the fact that the molecular products 
are dimers and hence alpha and beta subunits should be 
identified. HLA-DR is a special situation, as DRA is mostly 
monomorphic, but there are paralogues of DRB genes that 
are expressed in tight association with given DRB1 alleles. 
Typing of both prospective recipients and donors should be 
performed using molecular biology approaches, which vary 
according to the context, the timing and relative costs.
The importance of HLA typing for solid organs is 
twofold. On the one side, it can be used to choose the most 
compatible individual out of a pool of possible recipients. 
On the other side, it is essential to identify donors that are 
a priori incompatible for pre-immunized patients. In organ 
transplantation, the first scenario is important essentially 
for kidneys, while it is of limited significance in the case 
of lung, heart and liver transplants, which are life-saving 
procedures. The second scenario is critical for all patients: 
in this context, allelic typing of the donor may be important, 
particularly if the prospective recipient has allele-specific 
antibodies (3). 
The current guidelines of the Eurotransplant Network 
indicate that “every recipient and every organ donor must 
be typed for HLA-A, -B, -C, -DR, and -DQ. Serological 
and DNA typing for HLA-A and -B is accepted. For HLA-
DR, HLA-C and HLA-DQ” (www.eurotransplant.org). The 
guidelines of the European Federation of Immunogenetics 
for typing of patients in the lung transplant waiting 
l ist  indicate that typing should be performed for 
HLA-A, -B and -DR, if the patients are immunized 
(www.efi-web.org), implying that for non-immunized 
patients HLA typing is not strictly required, although 
performed by most Institutions. 
According to the results of this work and of others it 
would seem appropriate to perform HLA typing for all 
HLA Class II loci, and preferably at a high resolution. 
While expensive and possibly technically challenging 
for some centers, this approach would allow a systematic 
evaluation of donor-recipient compatibility both in 
retrospective and prospective settings, enabling a clearer 
assessment of the role of HLA mismatch. 
The related question that the work by Zhang and 
colleagues raises is how we should use improved HLA 
matching possibilities in the context of lung transplants. 
In the past 15 years, knowledge on HLA was improved by 
adding to genetic sequencing of the genes, data obtained 
from 3D structures of the HLA molecules, of the anti-
HLA antibodies and of the T cell receptors binding to 
host HLA molecules complexed with peptides derived 
from HLA molecules of the donor. The resolution of 
crystals containing anti-HLA antibodies bound to HLA 
alleles was the starting point for the identification of the 
contact regions that are critical to the antigen-antibody 
interaction (termed epitope for the antigen and paratope 
for the antibody) and to the definition of the so-called 
functional epitope or eplet, i.e., the minimal set of amino 
acids defining the binding, usually between 3 and 5 (4). It is 
therefore now possible to predict donor-recipient mismatch 
on the basis of the epitope matching, defining an eplet 
mismatch load (5). In a recent publication it was shown that 
this parameter is likely a more accurate predictor of DSA 
production and subsequent rejection in lung transplant 
recipients (6). In a second work, eplet mismatch for DR 
and DQ loci correlated against incidence of chronic lung 
allograft graft dysfunction (CLAD) (7). Interestingly, eplet 
mismatch was positively associated to restrictive allograft 
syndrome, but not to bronchiolitis obliterans. 
In addition to epitope matching, resolution of the T cell 
receptor structures, allowed the identification of the donor 
HLA-derived peptides that can indirectly activate an immune 
response in the host, when presented in association to the host 
HLA molecules (8). These discoveries constitute the basis for 
a new way of typing based on prediction of immunogenicity 
more than on simple sequence. This algorithm, termed 
PIRCHE for Predicted Indirectly Recognizable HLA 
Epitopes, determines compatibility between two individuals 
by defining the number of donor-derived HLA peptides that 
could be presented by recipient HLA Class II molecules to 
CD4+ T cells, thereby starting an immune response that could 
lead to T and B cell activation (9).
Accordingly, two donors with a similar degree of 
incompatibility on the basis of genetic analysis, may be very 
different in terms of eliciting a response in the recipient. 
There are now softwares that are freely available to the 
scientific community that can be of help in identifying the 
number of immunogenic eplets in the donor/recipient pair 
(HLA Matchmaker) and softwares that can predict the 
immunogenicity of donor HLA-derived peptides in a given 
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recipient (PIRCHE). 
While initial results using these softwares, such as the 
one presented in the work by Zhang and colleagues are 
encouraging, a note of caution should be raised concerning 
large-scale applicability of these procedures. In fact, even 
in the context of the work by Zhang and colleagues, 
high resolution typing for the donor—recipient pair was 
available only for about a third of all transplanted patients, 
underlining inherent technical difficulties and high costs. 
Accordingly, a prospective use is not so straightforward, 
at least in small to medium scale programs. Patients in the 
lung transplant waiting list may be in critical conditions 
and there may not be much room for choosing “the” most 
compatible donor, but simply “a” compatible donor. In 
addition, super selecting for HLA may pose significant 
limitations in terms of transplant accessibility in patients 
that have rare HLA alleles or that present a high degree of 
homozygosity.
A last consideration concerns the possibility of fine-tuning 
immune suppression for lung transplant recipients that are 
found to be high risk for developing CLAD or AR: if these 
findings will be independently validated and confirmed in 
larger cohorts, it will be possible to tailor immunosuppression 
according to the degree of both genetic mismatch and donor/
recipient immunogenicity. In this respect, the field needs 
clinical trials with immunomodulatory drugs, building on 
the experience obtained with rituximab. The availability of 
tailored therapeutic options will confirm the need to know 
as much as possible about the immunologic situation of 
the recipient, including HLA typing. Future work will tell 
whether this scenario can become real.
Acknowledgments
Funding: Work supported by a grant awarded by the 
Ministry of Education, University and Research-
MIUR Progetto strategico di Eccellenza Dipartimentale 
#D15D18000410001 to the Department of Medical 
Sciences, University of Turin. 
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
References
1. Zhang J, Liu D, Zhang C, et al. The value of high-
resolution HLA in the perioperative period of non-
sensitized lung transplant recipients. Ann Transl Med 
2020;8:37.
2. Edgerly CH, Weimer ET. The Past, Present, and Future 
of HLA Typing in Transplantation. Methods Mol Biol 
2018;1802:1-10.
3. Ju L, Suberbielle C, Li X, et al. HLA and lung 
transplantation. Front Med 2019;13:298-313.
4. Tambur AR. HLA-Epitope Matching or Eplet Risk 
Stratification: The Devil Is in the Details. Front Immunol 
2018;9:2010. 
5. Duquesnoy RJ. The eplet load concept in clinical 
transplantation. Pediatr Transplant. 2016;20:884-5.
6. Walton DC, Cantwell L, Hiho S, et al. HLA class II Eplet 
mismatch predicts De Novo DSA formation post lung 
transplant. Transpl Immunol 2018;51:73-5.
7. Walton DC, Hiho SJ, Cantwell LS, et al. HLA 
Matching at the Eplet Level Protects Against Chronic 
Lung Allograft Dysfunction. Am J Transplant 
2016;16:2695-703.
8. Guidicelli G, Taupin JL, Visentin J. Predicted indirectly 
recognizable HLA epitopes (PIRCHE): Only the tip of the 
iceberg? Am J Transplant 2018;18:521-2.
9. Geneugelijk K, Spierings E. PIRCHE-II: an algorithm 
to predict indirectly recognizable HLA epitopes in solid 
organ transplantation. Immunogenetics 2020;72:119-29.
Cite this article as: Deaglio S, Amoroso A, Rinaldi M, 
Boffini M. HLA typing in lung transplantation: does high 
resolution fit all? Ann Transl Med 2020;8(3):45. doi: 10.21037/
atm.2020.01.45
